Market Overview

TherapeuticsMD Shares Rally +27% On FBR's Initiation

Share:
Related
Jefferies' Best Biotech Ideas For 2016 (And Beyond)
TherapeuticsMD Plans On Raising $125 Million To Fund Commercialization Activities, Research & Clinical Trials

Shares of TherapeuticsMD (NYSE: TXMD) gained 27.6 percent following FBR's initiation. FBR analyst William Tanner initiated coverage on TherapeuticsMD with an Outperform rating and $34.00 price target.

Tanner reported that TherapeuticsMD's TX-001 is likely the only FDA approved bio-identical hormone formulation. The analyst added that the formulation could even change the way women are treated with hormone replacement therapy. FBR emphasized that the company is truly a “big deal” in regards to women's health.

The analyst further noted that TherapeuticsMD may attract a large pharma partner.

Shares of TherapeuticsMD closed at $4.13 on Monday. The stock gained 27.6 percent to $5.27 before seeing some selloff. The stock is currently up 24.4 percent.

Latest Ratings for TXMD

DateFirmActionFromTo
Jun 2015Guggenheim SecuritiesInitiates Coverage onBuy
Jul 2014FBR CapitalInitiates Coverage onOutperform
Jun 2014JMP SecuritiesInitiates Coverage onMarket Outperform

View More Analyst Ratings for TXMD
View the Latest Analyst Ratings

Posted-In: FBRAnalyst Color Health Care Price Target Initiation Hot Analyst Ratings General

 

Related Articles (TXMD)

Get Benzinga's Newsletters